Clinical Study of Tanshinone Capsules Against COVID-19

Exclusion Criteria

• •1. Patients at high risk of severe or critical illness and diagnosed as severe or critical illness before entering the study according to the "Diagnosis and Treatment Protocol for novel coronavirus Infection (Trial version 10)";
• •2. Received antiviral treatment before study entry, such as Chinese patent medicine or Chinese medicine formula treatment, Paxlovid, ritonavir tablets, SARS-CoV-2 monoclonal antibody treatment, convalescent plasma of convalescent patients, other clinical trial drugs indicated for COVID-19, etc. (except previous treatment for COVID-19 infection);
• •3. Subjects with known allergy to therapeutic drug tanshinone capsules or allergic constitution (including susceptible to allergic reactions to other drugs);
• •4. Suffering from diseases that seriously affect the immune system, such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.
• •5. Pregnant and lactating women;
• •6. Suspected bacterial, fungal, viral or other infections other than SARS-CoV-2 during the screening period;
• •7. Patients with bronchopneumonia, chronic lung abscess, chronic cough for more than 8 weeks, chronic pharyngitis with cough and other diseases before entering the study;
• •8. One of the following conditions during the screening period: 1) ALT or AST\>1.5 times ULN; 2) eGFR\<60mL/min; 3) hemoglobin \<8.0g/L, platelet \<5000/μL;
• •9. Patients who participated in other clinical trials within the past 3 months;